Proven safety profile
Most common side effects
Adverse reactions occurring in ≥3% of cancer patients receiving AKYNZEO® and cisplatin‑based, highly emetogenic chemotherapy (Cycle 1)1
In a single-cycle study of patients receiving cisplatin-based, highly emetogenic chemotherapy, 136 patients were treated with AKYNZEO.1
Adverse reactions occurring in ≥3% of cancer patients receiving AKYNZEO and anthracycline- and cyclophosphamide-based chemotherapy (Cycle 1)1
In a study of patients receiving AC-based chemotherapy, 725 patients were treated with AKYNZEO during Cycle 1, and 635 of these patients continued for up to 8 cycles in a multiple-cycle extension.